When the HIV/AIDS epidemic in sub-Saharan Africa needed affordable antiretroviral drugs at industrial scale, Laurus Labs was one of the companies that answered. Founded in 2005 in Hyderabad, it built the world’s most efficient anti-retroviral API manufacturing operation, then used that chemistry expertise to become one of India’s fastest-growing pharmaceutical CDMOs. Revenue grew from $159 million to $667 million in a decade.
Laurus Labs was founded on the insight that process chemistry — the science of manufacturing active pharmaceutical ingredients at scale, with high purity and low cost — is itself a core competence, not a commodity service. The company chose anti-retroviral drugs as its starting point because the chemistry was complex enough to create barriers to entry, the volumes were large enough to justify capital investment, and the global health need was urgent enough to guarantee demand.
By FY 2018, ARV APIs accounted for nearly 90% of Laurus’s revenue. The company supplied the raw materials for HIV treatment programmes across Africa, South Asia, and Latin America through partnerships with the Global Fund and national health ministries. Its manufacturing efficiency — built on continuous process improvement and vertical integration from intermediates through finished API — made it one of the lowest-cost producers in the world for first-line and second-line antiretroviral compounds.
A company that derives 90% of its revenue from a single therapeutic category is concentrated, not specialised. Laurus recognised the risk and began diversifying along two axes: therapeutic areas and the value chain. In therapeutic areas, it expanded from ARVs into oncology, cardiovascular, anti-diabetic, hepatitis C, and CNS APIs. In the value chain, it moved from supplying APIs to other companies into manufacturing finished dosage forms and providing full contract development and manufacturing services.
The results are visible in the FY 2025 business mix: four divisions — CDMO (custom synthesis for global pharma clients), Generics APIs, Generics Finished Dosage Forms, and Biotechnology. The biotechnology division, the newest, is building capabilities in cell and gene therapy manufacturing, positioning Laurus at the frontier of the next generation of pharmaceutical production.
Revenue surged 70% in FY 2021 to $578 million, peaked at $727 million in FY 2023, and settled to $667 million in FY 2025 as the pandemic-era demand normalised. But the underlying trajectory is clear: from $159 million in FY 2015, and from 1,800 employees to over 7,000.
Laurus serves pharmaceutical clients across the world, with 55% of FY 2025 revenue from rest-of-world markets (primarily low and middle-income countries for ARV programmes), 25% from Europe, and 20% from North America. The company operates fifteen manufacturing sites, primarily in India, with a facility in Japan acquired through its expansion into CDMO services. Its client base includes global innovator companies that contract Laurus for custom synthesis of intermediates and APIs.
Sources: Laurus Labs Annual Reports FY2014–15 through FY2024–25. US FDA facility registration data. Indian patent office records.